Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Taclonex Clear all
Terminated Phase 4 Interventional Results available

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NCT00924950
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis

NCT04227288
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Enstilar Foam
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

NCT01707043
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Taclonex
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 6, 2026, 1:36 PM EDT
Recruiting Phase 4 Interventional

Taltz in Combination With Enstilar for Psoriasis

NCT04372277
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

NCT00437255
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Fridley, Minnesota • Austin, Texas • Bryan, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy

NCT01761019
View directory record Official record
Conditions
Psoriasis
Interventions
Taclonex Topical Suspension
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

NCT03122353
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene and betamethasone suspension, Taclonex, Placebo
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug · Other
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
30
States / cities
Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

NCT03441789
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar, Vehicle, Otezla
Drug
Lead sponsor
L.H. Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%, SOR007 Ointment 0.15%, SOR007 Ointment Placebo, Taclonex® Ointment
Drug
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional

Enstilar in Combination With Biologic Agents

NCT03080545
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

NCT01083758
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
San Diego, California • Jacksonville, Florida • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

NCT00817219
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene plus betamethasone dipropionate ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Fremont, California • San Diego, California • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 6, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 6, 2026, 1:36 PM EDT
Recruiting Phase 4 Interventional

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

NCT03827876
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 6, 2026, 1:36 PM EDT
Completed No phase listed Observational

An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

NCT01982552
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Not listed
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Phoenix, Arizona • Fremont, California • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 6, 2026, 1:36 PM EDT
Not listed Phase 4 Interventional

The Maintenance Effect of Enstilar Foam in Combination With Otezla

NCT04555707
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast 30mg, calcipotriene and betamethasone dipropionate
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 6, 2026, 1:36 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

NCT00608777
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Calcipotriene/betamethasone
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 6, 2026, 1:36 PM EDT